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Abstract
Background: A rigorous research response is required to inform clinical and public health decision-making during an
epi/pandemic. However, the ethical conduct of such research, which often involves critically ill patients, may be
complicated by the diminished capacity to consent and an imperative to initiate trial therapies within short time frames.
Alternative approaches to taking prospective informed consent may therefore be used. We aimed to rapidly review
evidence on key stakeholder (patients, their proxy decision-makers, clinicians and regulators) views concerning the
acceptability of various approaches for obtaining consent relevant to pandemic-related acute illness research.
Methods: We conducted a rapid evidence review, using the Internet, database and hand-searching for English language
empirical publications from 1996 to 2014 on stakeholder opinions of consent models (prospective informed, third-party,
deferred, or waived) used in acute illness research. We excluded research on consent to treatment, screening, or other
such procedures, non-emergency research and secondary studies. Papers were categorised, and data summarised using
narrative synthesis.
Results: We screened 689 citations, reviewed 104 full-text articles and included 52. Just one paper related specifically to
pandemic research. In other emergency research contexts potential research participants, clinicians and research staff
found third-party, deferred, and waived consent to be acceptable as a means to feasibly conduct such research.
Acceptability to potential participants was motivated by altruism, trust in the medical community, and perceived value in
medical research and decreased as the perceived risks associated with participation increased. Discrepancies were
observed in the acceptability of the concept and application or experience of alternative consent models. Patients
accepted clinicians acting as proxy-decision makers, with preference for two decision makers as invasiveness of
interventions increased. Research regulators were more cautious when approving studies conducted with alternative
consent models; however, their views were generally under-represented.
Conclusions: Third-party, deferred, and waived consent models are broadly acceptable to potential participants, clinicians
and/or researchers for emergency research. Further consultation with key stakeholders, particularly with regulators, and
studies focused specifically on epi/pandemic research, are required. We highlight gaps and recommendations to inform
set-up and protocol development for pandemic research and institutional review board processes.
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Background
Infectious disease pandemics are recurrent but unpre-
dictable events that have a significant impact on the
health, economy and security of societies worldwide [1].
Emerging infections that lead to epidemic or pandemic
outbreaks arise at the human-animal interface [2]. The
amplification and spread of these diseases can result in
outbreaks and epidemics that may develop into a public
health emergency. A pandemic occurs when there is
global spread of the disease [1]. The World Health
Organisation (WHO) monitors and reports pandemics
in terms of global phases – inter-pandemic, alert, pan-
demic and transition [3]. These phases are designed to
inform national pandemic risk management strategies
and actions. Through all phases, expedient, high-quality
epidemiological and clinical research is essential to in-
form clinical and public health decision-making [4].
Such research has the potential to shift the trajectory of
a pandemic [5, 6]. The need to develop research pre-
paredness alongside clinical and public health response
preparedness has been recognised increasingly. Some
progress has been made in strengthening surveillance
systems and in the development and testing of new vac-
cines. However, the experiences of attempting to con-
duct research during recent epi/pandemics, such as the
2009 H1N1 influenza pandemic and the 2014 outbreak
of Ebola in West Africa, indicate that a timely and ef-
fective research response is often not possible [7].
Hospitals and critical care units, in particular, are at the
front line of caring for the most severely ill patients and
act as the canary in the coalmine during an epi/pandemic
in the initial phase of an outbreak [6, 8, 9]. They are also
at the forefront of generating important new knowledge
about incidence, outcome, infection control, case presen-
tation, resource utilisation and optimal clinical care and
are well placed to provide crucial information to inform
both clinical and public health decision-making [10]. Con-
sequently, there is a need to develop both clinical and re-
search pandemic preparedness in critical care units [10].
Clinical research conducted during a pandemic should be
held to the same high standards of scientific and ethical
rigour as that conducted during non-emergent times.
Legislative and moral codes of practice [11] set out the
ethical requirements for research, which include that it
has value in advancing health or knowledge, that is it
methodologically sound and scientifically valid, that the
benefit to the individual and society outweighs the risks,
and that research participants provide informed consent
[12]. Most hospital-based research is subject to review and
approval by an independent regulatory body. During the
H1N1 pandemic, clinical research was hampered by delays
in obtaining these ethical and regulatory approvals, as well
as by other factors, such as accessing funding and site re-
cruitment. As a result initial pandemic waves had largely
passed by the time recruitment for these studies was ready
to commence [10, 13]. As a consequence, recommenda-
tions have been made for organised and integrated re-
search preparedness for pandemics and epidemics [14].
This includes the need for operational research capacity,
during inter-pandemic periods (‘peace-time’) that can be
activated rapidly and effectively when the need arises [7,
10, 15]. Inter-pandemic activities to achieve preparedness
include the design and pre-approval of study protocols
[16] and the establishment of centralised, rapid regulatory
approval processes [4, 7].
One of the challenges to conducting clinical research
at varying stages of a pandemic is obtaining valid in-
formed consent from participants affected by the pan-
demic. Consent is central to the principle of respect for
patient autonomy and is an integral part of ethical bio-
medical research [11]. For informed consent to be valid,
participants should receive sufficient information about
the study, including the risks involved, for them to make
an informed choice about participation; they should
understand this information; and they should be compe-
tent to decide and to make the decision voluntarily, that
is, in the absence of coercion. Potential participants
should understand that they have a right to refuse as
well as to withdraw from a study without fear of any
consequences [11]. However, many forms of illness with
pandemic potential have clinical consequences that re-
sult in diminished capacity to consent for many affected
patients. Moreover, for some research questions there is a
time imperative for recruitment of individual research par-
ticipants. These issues create challenges for planning and
conducting research during possible future pandemics.
These challenges are not unique to pandemics, but, ra-
ther, are generic to studying any form of critical illness that
results in the diminished capacity to consent. There are
several alternatives to prospective informed consent that
allow research to be conducted ethically when participants
lack the capacity to provide informed consent. We identi-
fied three alternative models in Table 1, namely, third-party
consent, deferred consent and waived consent. These alter-
native consent processes have made it feasible to conduct
emergency or critical care research that would not other-
wise be possible [17, 18]. Researchers have highlighted the
utility of these models when designing protocols for pan-
demic research [4], and existing pandemic protocols use
hybrid models proportionate to the level of pandemic risk
and based on an assessment of patient capacity and avail-
ability of a surrogate consenter [19, 20].
We review the evidence on acceptability of these differ-
ent consent models from the perspective of different
stakeholders. In the absence of pandemic-specific re-
search, we have looked to emergency research more
broadly as it shares many of the features that we might ex-
pect in hospital based pandemic research. These features
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are a lack of participant capacity, sometimes in combin-
ation with a research question in which the decision to
participate is time-critical. The objectives of this review
are to broadly map this terrain, to identify recommenda-
tions that are relevant to investigators that plan to develop
protocols for pandemic research, and to identify further
empirical work that might allow researchers to implement
these new procedures in a way that is most acceptable to
all stakeholder groups.
Methods
Rapid review methodology offers a structured and efficient
approach to synthesising evidence to inform decision-
making [21, 22]. They are conducted in a shorter time
frame than full systematic reviews, but retain most of the
methodological rigour by using systematic and reprodu-
cible methods. Rapid reviews produce similar conclusions
to systematic reviews that are sufficient for policy and
clinical decision-making [23]. The principles of a rapid re-
view are that decisions taken to expedite the review
should be transparent, that the purpose is clearly enunci-
ated, and that potential limitations are acknowledged. To
expedite our review we limited our search by year (1996
onward) and language (English language only), 70 % of
citations were screened by a second researcher, a single re-
searcher conducted data extraction and quality assessment
of each paper, and our analysis involved description and
categorisation as opposed to more formal approaches such
as meta-summary [22].
Eligibility criteria
We included empirical research using qualitative, quantita-
tive, or both methods that aimed to report the views of
potential research participants, their proxy decision makers,
clinicians, or research regulators regarding the different
models of consent for participation in emergency research.
We included paediatric research but excluded neonatal re-
search due to the unique ethical issues arising in this kind
of research [24]. English language publications of research
conducted in OECD countries from 1996 onward were in-
cluded. We excluded studies on consent for elective treat-
ment, end-of-life decisions, vaccinations, screening, genetic
testing, organ donation and/or other clinical procedures.
Studies reporting on research participation that did not in-
clude consent, for example, reports of recruitment or ef-
forts at retention, were also excluded, as were descriptive
studies reporting on the consent process without evaluating
participant experience or studies on the features of consent
documents. Finally, the following types of articles were also
excluded: opinion pieces, commentaries, editorials, unpub-
lished dissertations, conference abstracts, book chapters,
conference reports, protocol papers and reviews.
Information sources
We searched the following databases in November 2014:
MEDLINE, EMBASE, PsycINFO, Health Management
Information Consortium (HMIC) via OvidSP; Science
Citation Index Expanded (SCI-EXPANDED), Social Sci-
ences Citation Index (SSCI) via Web of Science SSI;
Cochrane Central; and OpenGrey. We also searched
WHO publications via their website, and hand-searched
the following journals from October 2012–2014: Inten-
sive Care Medicine, Journal of Medical Ethics, BMC
Medical Ethics and Critical Care Medicine. Finally, refer-
ence lists of included articles and review articles were
mined to identify other relevant citations.
Table 1 Definitions of terms
Emergency research Research including intensive and critical care research that relates directly to a life-threatening or debilitating condition
in which there is a time-imperative for intervention.
Capacity to consent The person should have the capacity to make a choice about the proposed course of action, knows about the
study risks, benefits and alternatives, understands that consent is ‘voluntary and continuing permission’, and
understands that consent can be withdrawn at any time.
Prospective informed consent The decision (written, dated and signed) to take part in a study, which is taken after the person is fully informed
about the study nature, its significance, implications and risks. Informed consent can be given by any person
capable of giving consent or, where the person is not capable, by a surrogate decision maker. Oral consent in the
presence of a witness may be given in exceptional cases.
Third-party consent Informed consent to research participation is provided by a surrogate or proxy decision maker, for example, a
family member or legal representative where the potential participant is unable to provide consent themselves.
Proxy consent can also describe the process by which people with the legal right to consent for themselves or as
a surrogate can delegate that right to another person.
Deferred consent When a patient is enrolled into a study, and consent is taken later, either from a surrogate decision maker or from
the patient when he/she is able to provide informed consent.
Waiver of consent and Exception
from informed consent
A consent procedure that alters elements of informed consent or waives the requirements to obtain informed
consent. For example consent may be waived if the research presents no more than minimal risk of harm to
subjects and could not be carried out without a waiver.
Exception from informed consent may also apply for enrolment of participants in emergency research. Here,
requirements include consultation with representatives of and public disclosure to the communities in which the
study will be conducted prior to study initiation. Deferred consent is still a requirement in most cases.
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Search strategy
The search strategy was developed using two concepts
and synonyms– informed consent and emergency care.
In addition, we used an adapted search filter for partici-
pant views [25] to enhance the specificity of the search.
The full search strategy is available in Additional file 1:
Appendix A.
Study selection
A single researcher (NG) reviewed titles and abstracts
against the inclusion criteria. Where a decision could
not be made on the title and abstract alone, full texts
were retrieved. A second researcher (MG) independently
reviewed 70 % of this sample (n = 482). Discrepancies
were resolved by consensus.
Quality assessment
A single researcher completed quality checklists, including
risk of bias, for each paper (NG – 48 papers; MG − 3 pa-
pers). For surveys, items adapted from Bennett et al. [26]
were used, and for qualitative research, the Critical Ap-
praisal Skills Program (CASP) checklist [27] was used.
Data extraction
A single researcher extracted data (study characteristics, con-
sent model, stakeholder group, and acceptability evidence)
using a pre-developed data extraction tool (NG – 48 papers,
MG – 3 papers).
Analysis
Studies were categorised according to the consent model
(informed, third-party, deferred, or waived) and stake-
holder group (participants and their proxy decision-
makers, clinical and/ or research staff and regulators).
We grouped studies looking at participant views to-
gether with those looking at both participant and their
proxy decision maker. Key themes related to the accept-
ability of each model were summarised across each sub-
group [22].
Results
Study selection
We screened 695 titles and abstracts and identified 104
potentially relevant articles. Of these, 52 were excluded
due to study features (n = 18), non-OECD country (n = 6),
non-emergency research (n = 4), no consent for research
participation (n = 3) or no assessment of views (n = 21)
(Fig. 1). Our final sample included 52 papers (Tables 2,
3, 4 and 5).
Study characteristics
Our sample comprised studies using quantitative (n = 37),
qualitative (n = 11), or mixed methods (n = 4). The
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Fig. 1 PRISMA flow diagram of the selection and inclusion of publications
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Table 2 Characteristics of the included study – prospective informed consent
Reference Country Clinical context Study design Study aim Scenario: real or hypothetical Study sample
Respondents Direct experience
of clinical context
or condition
Direct experience
of consent model
Potential research participants
Qualitative or mixed methods studies
1. Agard 2001 Sweden Acute myocardial
infarction
Mixed
methods
Investigate patient
experience of consent
process
Studies of early phase of treatment
for myocardial infarction
31 trial participants Yes Yes
2. Blixen 2005a USA Stroke Qualitative
(interview)
Evaluate preferences or
values
Hypothetical study – emergency
stroke research
12 stroke patients Yes No
3. Gammelgaard
2004a
Denmark Acute myocardial
infarction
Qualitative
(interviews)
Investigate patient
experience of consent
process
Clinical trial comparing intervention
(primary angioplasty) with medical
strategy (fibrinolysis)
32 trial candidates (23
participants, 9 who did
not consent)
Yes Yes
4. Mangset 2008 Norway Stroke Qualitative
(interviews)
Investigate patient
experience of consent
process
Clinical trial evaluating thrombolytic
drug treatment for stroke
11 trial participants Yes Yes
Survey studies
5. Chenaud 2009a Switzerland ICU Survey (Self-
administered)
To evaluate preferences Hypothetical scenarios of ICU research 67 patients; 52 relatives
from recent ICU admission
Yes No
6. Gammelgaard
2014b
Denmark Acute myocardial
infarction
Survey (Self-
administered)
Investigate experience of
consent process
Clinical trial comparing intervention
(primary angioplasty) with medical
strategy (fibrinolysis)
181 trial candidates (103
participants, 78 who did
not consent)
Yes Yes
7. Gigon 2013 Switzerland ICU Survey (self-
administered)
Evaluate choice Hypothetical scenarios of ICU research 185 patients, 125 relatives
following ICU discharge
Yes No
8. Paradis 2010 USA ED research Survey
(interview)
Investigate perspectives
on consent process
10 studies involving cardiac conditions 150 study participants Yes Yes
9. Schats 2003a Netherlands Stroke Survey
(interview)
Post-trial evaluation. Two clinical trials that evaluated
interventions for subarachnoid
haemorrhage
49 patients; 47 relatives
(trial participants)
Yes Yes
10. Williams 2003 Australia,
New Zealand
Acute myocardial
infarction
Survey
(interview)
Evaluation of consent for trial Clinical trial of two antithrombin
therapies for acute myocardial
infarction
399 trial candidates Yes No
11. Yuval 2000 Israel Acute myocardial
infarction
Survey (Self-
administered)
Post-trial evaluation Large trial evaluating therapies for
acute myocardial infarction
129 trial participants Yes Yes
Clinical, research staff and regulators
Qualitative or mixed methods studies
12. Chamberlain
2009b
USA Paediatrics –status
epilepticus
Qualitative
(focus groups)
Evaluation during trial Pharmacokinetic study evaluating
lorazapam for status epilepticus
18 research staff Yes Yes
acompares different consent models
bpaediatrics
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Table 3 Characteristics of included studies – third-party consent
Reference Country Clinical context Study design Study aim Scenario: real or hypothetical Study sample
Respondents Direct experience
of clinical context
or condition
Direct experience
of consent model
Potential research participants
Qualitative or mixed methods studies
13. Ali 2006 UK Stroke Mixed methods Inform clinical trial
design.
Proposed trial evaluates the effect of
routine oxygen supplementation after
acute stroke
49 stroke patients, 24
carers
Yes No
14. Blixen 2005a USA Stroke Qualitative
(interview)
Evaluate
preferences or
values
Hypothetical study – emergency
stroke research
12 stroke patients Yes No
15. Koops 2002 UK Stroke Mixed methods Inform study
design.
Proposed study evaluates thrombolysis
for acute ischaemic stroke
54 stroke patients and
carers
Yes No
Survey studies
16. Barrett 2012 Canada ICU Survey (interview) Evaluate attitude
or opinion
Hypothetical scenarios of ICU research 136 surrogate decision
makers of critically ill
patients (adults and
children)
Yes No
17. Biros 2009a USA Status seizure
–
Survey (self-
administered)
Part of a public
consultation prior
to trial initiation.
Proposed trial evaluates pre-hospital
intervention for status seizures
1901 community members No Some
18. Chenaud
2009a
Switzerland ICU Survey (Self-
administered)
Evaluate
preferences
Hypothetical scenarios of ICU research 67 patients; 52 relatives
from recent ICU admission
Yes No
19. Clark 2013 UK Neurosurgery Survey (Self-
administered)
Part of a public
consultation prior
to trial initiation.
Proposed study evaluates surgical
techniques
171 patients and carers in
neuro-surgical clinic
No No
20. Gigon 2013 Switzerland ICU Survey (self-
administered)
Evaluate choice Hypothetical scenarios of ICU research 185 patients, 125 relatives
following ICU discharge
Yes No
21. Kamarainen
2012c
Finland Cardiac arrest Survey (Self-
administered)
Post-trial
evaluation.
Trial evaluated pre-hospital
intervention for cardiac arrest
11 patient; 17 consent
providers; 13 physicians
(trial participants)
Yes Yes
22. Perner 2010 Denmark ICU Survey (self-
administered)
Assess attitudes Hypothetical trials and new medications 42 next-of-kin of uncon
scious ICU patients
Yes No
23. Scales 2009a Canada Critical illness Survey (interview) Survey preferences Hypothetical study scenarios of
research during critical illness
240 survivors of critical illness Yes No
24. Schats 2003a Netherlands Stroke Survey (interview) Post-trial
evaluation.
Two trials that evaluated interventions
for subarachnoid haemorrhage
49 patients; 47 relatives
(trial participants)
Yes Yes
25. Stephenson
2007
Australia Emergency care Survey (self-
administered)
Attitudes survey Hypothetical scenarios of critical
care research
185 patients Possible No
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Table 3 Characteristics of included studies – third-party consent (Continued)
Clinical, research staff or regulators
Survey studies
26. Burns 2013 Canada Pandemic
research
Survey (self-
administered)
Evaluate
experiences, beliefs
and practices
Hypothetical -pandemic research 168 administrative and clinical
staff involved in H1N1
pandemic research
Yes Yes
27. Cook 2008c Canada, Australia,
New Zealand
Critical illness Survey (self-
administered)
Evaluate
experience, beliefs,
and practices
Hypothetical – enrolment of
critically ill children and adults
284 clinicians caring for
critically ill patients
Yes Yes
28. Duffett 2011a Canada Critical care
research
Survey (self-
administered)
Evaluate attitudes
and beliefs
Hypothetical scenario of double-
blind, placebo-controlled, RCT
evaluating single dose of
medication perceived by REB as
minimal risk
98 ICU researchers; 52 members
of hospital research ethics boards.
Yes Possible
29. Kompanje
2005a
Netherlands Traumatic
brain injury
Survey (self-
administered)
Evaluate opinions Hypothetical -clinical emergency
care
79 neuro-trauma clinical staff
across 19 European countries
Yes Possible
acompares different consent models
bcompares different stakeholder groups
cpaediatrics
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Table 4 Characteristics of included studies – deferred consent
Reference Country Clinical context Study design Study aim Scenario: real or hypothetical Study sample
Respondents Direct experience
of clinical context
or condition
Direct experience
of consent model
Potential research participants
Qualitative or mixed methods studies
30. Woolfall 2014b UK Paediatric – status
epilepticus
Qualitative (focus
groups, interviews)
Inform study design Proposed trial evaluating new
treatment for status epilepticus
17 parents Mixed No
Survey studies
31. Chenaud 2009a Switzerland ICU Survey (Self-
administered)
Evaluate preferences Hypothetical scenarios of ICU
research
67 patients; 52 relatives
from recent ICU admission
Yes No
32. Gamble 2012b UK Meningitis Survey (self-
administered)
Investigate views Proposed trial evaluating two
currently used treatments for
emergency resuscitation and
treatment
68 families Yes No
33. Gigon 2013a Switzerland ICU Survey (self-
administered)
Evaluate choice Hypothetical scenarios of ICU
research
185 patients, 125 relatives
following ICU discharge
Yes No
34. Potter 2013 Australia ICU Survey (self-
administered)
Post-trial evaluation Clinical trial evaluating two
strategies for maintaining
blood sugar in ICU
210 trial participants Yes Yes
35. Scales 2009a Canada Critical illness Survey (interview) Survey preferences Hypothetical study scenarios of
research during critical illness
240 survivors of critical
illness
Yes No
Clinical, research staff or regulators
Survey studies
36. Cook 2008b Canada, Australia,
New Zealand
Critical illness Survey (self-
administered)
Evaluate experience,
beliefs, and practices
Hypothetical – enrolment of
critically ill children and adults
284 clinicians caring for
critically ill patients
Yes Yes
37. Duffett 2011a Canada Critical care
research
Survey (self-
administered)
Evaluate attitudes
and beliefs
Hypothetical scenario of
double-blind, placebo-controlled,
RCT evaluating single dose of
medication perceived by REB as
minimal risk
98 ICU researchers; 52
members of hospital
research ethics boards.
Yes Possible
38. Woolfall 2013b UK Paediatric – status
epilepticus
Survey (self-
administered)
Evaluate views and
experiences
Hypothetical 45 clinical staff Yes Mixed
acompares different consent models
bpaediatrics
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Table 5 Characteristics of included studies – waived consent
Reference Country Clinical context Study design Study aim Scenario: real or hypothetical Study sample
Respondents Direct experience
of clinical context
or condition
Direct experience
of consent model
Potential research participants
Qualitative or mixed methods studies
39. Blixen 2005a USA Stroke Qualitative
(interview)
Evaluate
preferences or
values
Hypothetical study – emergency
stroke research
12 stroke patients Yes No
40. Dickert 2009 USA Cardiac arrest Qualitative
(interview)
Assess views Hypothetical study scenarios for
research emergency research
22 sudden cardiac death
survivors
Yes No
41. Kasner 2011 USA Acute neurologic
emergency
research
Qualitative (focus
group)
Evaluate views on
community
consultation
Hypothetical study Patients with previous stroke
or brain injury, their families,
and people at risk for
traumatic brain injury
(n = 40)
Yes No
42. Morris 2004 USA Paediatrics Qualitative (focus
group and
interview)
Public consultation Proposed in-patient paediatric
resuscitation clinical trial
23 parents from PICU of
children who had been
resuscitated; 33 staff
Yes No
43. Raymond 2010 USA Paediatric
resuscitation
Mixed methods Evaluation of public
disclosure
Proposed in-patient resuscitation
clinical trial
93 parents attending a PICU Yes No
44. Richardson 2005 USA Cardiac arrest Qualitative (focus
group)
Explore attitudes
about emergency
research without
consent
Clinical trial evaluating pre-hospital
intervention for cardiac arrest
42 participants from
community where study
being conducted
No No
45. Shah 2003 USA Emergency Qualitative
(content analysis)
Recommendations
for public
disclosure
Documentation for real studies 4 studies from repository of
mandatory documents
N/A N/A
Survey studies
46. Abboud 2006 USA Cardiopulmonary
arrest
Survey (interview) Evaluate
willingness to
participate
Hypothetical scenarios –
intervention resuscitation research
207 Patients attending an
emergency department and
a 213 geriatric clinic
Mixed No
47. Baren 1999 USA Paediatric Survey (interview) Public consultation
(feasibility testing)
Hypothetical clinical trial evaluating
treatment for posttraumatic seizures
227 Parents of children
treated in the emergency
department
Yes No
48. Biros 2009a USA Status seizure – Survey (self-
administered)
Part of a public
consultation prior
to trial initiation.
Proposed trial evaluates pre-hospital
intervention for status seizures
1901 community members No Some
49. Booth 2005 UK Cardiac arrest Survey (self-
administered)
Assess attitudes Hypothetical – emergency research 361 patients attending an
emergency department
No No
50. Bulger 2009c USA Resuscitation Survey (interview) Public consultation Clinical trials evaluating pre-
hospital interventions for cardiac
arrest and traumatic injury
2418 representative sample
of community
No No
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Table 5 Characteristics of included studies – waived consent (Continued)
51. Dickert 2013 USA Status epileptics Survey (interview) Assess experience
and effect of public
consultation
Clinical trial of a pre-hospital
comparing pharmacological
interventions for status epileptics
24 patients; 37 surrogate
decision makers
Yes Yes
52. Dickert 2014b USA Acute traumatic
brain injury
Survey (various
methods)
Survey nested in
public consultation
Clinical trial evaluating progesterone
for treatment of traumatic brain
injury
2612 community
consultation participants
No No
53. Longfield 2008 USA Traumatic
haemorrhagic
shock
Survey (self-
administered)
Description of
public consultation
Clinical trial evaluating a pre-hospital
intervention for traumatic
haemorrhagic shock
150 community meeting
attendees
No No
54. McClure 2003 USA Resuscitation Survey (interview) Evaluation of
views and public
awareness of EFIC
research
Studies conducted under waived
consent (details unclear)
Convenience sample of 530
patients attending a hospital
emergency department
No No
55. Morris 2006 USA Paediatric
resuscitation
Survey (interview) Assess feasibility of
public consultation
Hypothetical scenarios of in-patient
resuscitation clinical trials
91 parents attending a PICU Yes No
56. Nelson 2013 USA Cardiac arrest Survey (interview or
self-administered)
Evaluation of
patient opt-out
experience
Clinical trial evaluating a pre-hospital
intervention for cardiac arrest
46 community members
who had opted out of
participation in a study
conducted under waived
consent.
No No
57. Ramsey 2011 USA Emergency
research
Survey (interview) Evaluation of public
consultation
methods
Clinical trials conducted under
waived consent (detailed unclear)–
Community where study
being conducted –(baseline,
n = 390; 11 months later,
n = 325)
No No
58. Scales 2009a Canada Critical illness Survey (interview) Survey preferences Hypothetical study scenarios of
research during critical illness
240 survivors of critical
illness
Yes No
59. Smithline 1998 USA Emergency
research
Survey (interview) Evaluate opinions Hypothetical study scenario of
acute care research
Convenience sample of
patients in an emergency
department 212
No No
60. Triner 2007 USA Traumatic
haemorrhagic
shock
Survey (self-
administered)
Evaluation of
effectiveness of
public disclosure
Clinical trial evaluating a pre-hospital
intervention for traumatic
haemorrhagic shock
Convenience sample of
patients to emergency
department 497
Mixed No
Clinical, research staff or regulators
Qualitative studies
61. McClure 2007 USA Resuscitation Qualitative
(interviews)
Evaluate experience Hypothetical – based on
experience of protocol review
10 institutional review board
members
Yes Yes
Survey studies
62. Cook 2008c Canada, Australia,
New Zealand
Critical illness Survey (self-
administered)
Evaluate
experience, beliefs,
and practices
Hypothetical – enrolment of
critically ill children and adults
284 clinicians caring for
critically ill patients
Yes Yes
63. DeIorio 2007 USA Resuscitation Survey (self-
administered)
Understand
attitudes
Hypothetical – based on
experience of protocol review
69 research ethics board
chairpersons
Yes Mixed
G
obat
et
al.Trials
 (2015) 16:591 
Page
10
of21
Table 5 Characteristics of included studies – waived consent (Continued)
64. Dickert 2014a USA Status epilepticus Survey (self-
administered)
Assess views and
experience of
public consultation
Clinical trial of pre-hospital
intervention for status epilepticus
28 research staff Yes Yes
65. Duffett 2011a,b Canada Critical care
research
Survey (self-
administered)
Evaluate attitudes
and beliefs
Hypothetical scenario of double-
blind, placebo-controlled, RCT
evaluating single dose of medication
perceived by REB as minimal risk
98 ICU researchers; 52
members of hospital
research ethics boards.
Yes Possible
66. Kompanje 2005a Netherlands Traumatic
brain injury
Survey (self-
administered)
Evaluate opinions Hypothetical -clinical emergency
care
79 neuro-trauma clinical
staff across 19 European
countries
Yes Possible
67. Schmidt 2009 USA Severe traumatic
injury
Survey (self-
administered)
Evaluate opinions
and experience of
research staff
Real study of pre-hospital
intervention for severe trauma
844 emergency medical
technicians participating in
the trial
Yes Yes
acompares different consent models
bcompares different stakeholder groups
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number of participants in the studies ranged from 10 to
54 for qualitative studies and from 11 to 2,612 for sur-
vey studies. Several studies covered more than one
consent model (n = 9) or considered more than one
stakeholder view (n = 2).
Fewer studies considered the perspectives of clinical or
research staff compared with potential research partici-
pant views, and just one study included regulator per-
spectives of third-party and deferred consent [28].
Quality assessment
The quality of reporting of qualitative studies was gener-
ally high with most studies and provided a clear state-
ment of research objective (n = 13; 93 %), appropriate
use of qualitative methodology (n = 13; 93 %), and evi-
dence of rigorous analysis (n = 9; 64 %).
The quality of reporting for survey studies was vari-
able. The majority reported clear study objectives (n =
34; 95 %), methods of survey administration (n = 38;
100 %), and data analysis (n = 33; 86 %). While most pa-
pers gave some description of the research tool (n = 31;
82 %), just over half (n = 21; 55 %) described how the
tool was developed and pretested (n = 23; 60 %). Few pa-
pers (n = 6; 16 %) described efforts to validate these
tools. Limitations across most studies included unclear
or limited representativeness of the sample (n = 21;
55 %), influence of non-response bias (n = 21; 55 % re-
ported this) and unclear or limited generalizability of
findings (n = 32; 84 %).
We did not exclude any studies on the basis of our
quality assessment.
Prospective informed consent
Potential research participants
Included studies evaluated the experience of patients who
had the capacity to consent to emergency research partici-
pation, for example, myocardial infarction, stroke or gen-
eral ICU research (n = 11) [29–39]. Much of this research
was conducted with patients who had been approached to
participate in trials, including both those who had con-
sented and, in some cases, those who had not [32, 38, 39].
Views about the acceptability of prospective informed
consent were mixed. While some participants expressed
the importance of being given the opportunity to consent,
saying that it was important for maintaining dignity
[31, 38], others were opposed to being asked to make such
a decision in the face of severe illness, with some even in-
dicating that it was immoral [29, 38].
Even when a patient did provide consent, however,
the process arguably might not have met the require-
ment for patients to be fully informed before doing so
[29, 32, 36–38]. Evaluations of two clinical trials investigat-
ing treatments for acute myocardial infarction found that
19 % of 367 [36] to 28 % of 103 [32] research participants
and 7 % of 78 [32] to 8 % of 32 [36] of non-participants
read the information sheet, and a mismatch existed be-
tween the educational level required to comprehend
the information sheet and that of the majority of partic-
ipants in one study [36]. However, the perception of
participants in other trials was that they were capable
and sufficiently informed to make a decision and had
enough time to do so [32, 34, 39].
Research staff and regulators
Researchers and clinicians highlighted similar concerns
about how truly informed parents were when providing
consent in paediatric emergency research [40]. High
levels of parental distress and anxiety, lengthy and de-
tailed documents, and the high-pressured clinical envir-
onment were key barriers identified to this consent
process. No papers assessed the views of regulators or of
researchers in adult populations in emergency research
where patients were deemed to have capacity.
Third-party consent
Potential research participants
Two survey studies on consent in the ICU setting re-
ported that more than 85 % of research participants and
their relatives found third-party consent to be acceptable
(87 % of 240 [41] and 85 % of 137 [41]). There was a
small decline in acceptability when risk increased
(greater risk of complications in a placebo controlled
randomised controlled trial (RCT) or participants had
less time to decide (<3 hrs versus 24 hrs) [42]. Patients
(n = 240) who had survived critical illness also indicated
third-party consent as their preferred consent model in
a low- (76 %) and higher- (81 %) risk study and where
two low-risk treatments were compared (77 %). The
study reporting the most negative views was a question-
naire study involving people in waiting rooms at emer-
gency departments and intensive care units (ICUs) in
Australia. In response to a hypothetical question about
how they would feel about a relative providing consent
for them to be involved in research in the event of a crit-
ical illness, 26 % were strongly in favour, 55 % were neu-
tral, and 19 % were against this [43]. No consistent
demographic factors associated with acceptability were
noted across studies.
Members of the public consulted about study design
were accepting of third-party consent and the need for
alternative consent models, considering them necessary
to feasibly conduct emergency research [44–47]. Patients
and carers involved in the design of a low-risk (oxygen
supplementation) [46] and a higher-risk (thrombolysis)
[47] study saw value in the need for stroke research and
for adaptations to informed consent processes that
might make such research feasible. A survey conducted
as part of community consultation for a trial evaluating
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a pre-hospital intervention for seizures found that 78 %
(n = 1901) of respondents supported the concept of
third-party consent, and 65 % indicated willingness to be
enrolled with the consent of a family member even if
there was no direct benefit to themselves [44]. A com-
munity consultation for a neurosurgical trial found 91 %
(n = 171) of participants were accepting of surrogate
consent by a doctor independent of the trial [45].
Two studies evaluated the experience of patients and
surrogate decision makers after their involvement in re-
search conducted using third-party consent. In a post-trial
evaluation of a small pre-hospital study evaluating thera-
peutic hypothermia after cardiac arrest, fewer than half of
patients (45 % of 11) and clinician proxy decision makers
(46 % of 13) felt consent had been necessary at all under
emergency research conditions, while 71 % of 17 spouses
felt some form of consent was necessary [48]. Reasons for
this discrepancy are not clear; however, it appears that pa-
tients and surrogate decision makers would consider de-
ferred consent as an alternative in this context.
In a study with patient-relative pairs in ICU, most re-
spondents wanted the patient to decide about research
participation if they were able (75 % of 67 patients and
77 % of 52 relatives) when considering hypothetical sce-
narios [31]. In a second study, a third of patients and
their relatives (31 % of 185) wanted someone other than
the patient to give consent, even if the patient had cap-
acity, particularly if the study was invasive (prospective
randomised trial, with small risk and potential benefit)
[33]. One conclusion reached from these studies was
that patients should be given a choice about who should
consent on their behalf with the option for a proxy deci-
sion maker even when patients are conscious. When
asked, patients seemed to have a proxy in mind includ-
ing support for a physician to act as a proxy decision
maker [30, 33]. Invasiveness of a study (that is, a low-
risk RCT versus observational research) did not impact
preference for who should consent [33]. In a small study
of patients who had experienced out-of-hospital cardiac
arrest, all patient respondents (100 %, n = 11) agreed (at
least to some extent) that the consent provider was able
to consent on their behalf, and 88 % of spouses (n = 16)
agreed that they were capable of providing consent [48].
However, the clinicians were more sceptical about
spouses’ ability to make these decisions due to the emo-
tional impact of making a decision at such a time. In
other studies patients and/ or family members expressed
a preference for two decision makers, particularly when
a study is invasive or of higher risk, as this may alleviate
the burden on the proxy decision maker [31, 33, 49].
Research staff and regulators
Clinical researchers endorsed third-party consent models
in order to feasibly conduct critical care research; however,
they had concerns about the capacity of proxy decision
makers to consent on their relative’s behalf, both in a
survey related to traumatic brain injury research
(hypothetical) (48 %, n = 78) [50] and in a real low-
risk trial of therapeutic hypothermia after cardiac ar-
rest (61 %, n = 13) [48].
Compared with research regulators, surveyed re-
searchers endorsed third-party consent provided by two
independent physicians for a hypothetical placebo-
controlled trial evaluating a single dose of medication
considered to be low risk for patients with cardiac arrest
when a surrogate decision maker was not available (46.4
to 54.1 % of 98 researchers versus 10.0 to 18.0 % of 52
regulators, <0.001 ([28]). However, neither group found
consent by the attending interventionist involved with
the trial acceptable (12.4 to 15.3 % of 98 researchers and
2 % of 52 regulators). The authors suggest that these
findings may reflect the different remits of respondents:
while both are concerned with the safety and integrity of
research processes, researchers additionally are concerned
with feasibility and timely completion of research. A sur-
vey of ICU clinical researchers considered consent by two
independent physicians effective when a surrogate deci-
sion maker was not available (rated 6, IQR = 5,7 on a 7
point scale, n = 284); however, views on the ethics (4,
IQR = 3,6, n = 284, and feasibility (5, IQR = 3,6, n =
284,) of this approach varied [51].
We identified just one paper specific to pandemic re-
search [52]. In a Canadian cross-sectional survey, 74 %
of 39 research coordinators and 51 % of 139 administra-
tors with experience of conducting research during the
H1N1 pandemic agreed that alternatives to third-party
consent prospective were required in order to effectively
recruit participants to pandemic research studies [52].
Just 14.4 % of 39 of research coordinators and 5.1 % 139
of administrators disagreed with this concept. Alterna-
tive models would include adaptations to third-party
consent (for example, consent being provided by two cli-
nicians, deferred consent, or waived consent).
Deferred consent
Potential research participants
Participants in a low-risk observational study in
Australia reported high levels of satisfaction with their
enrolment using deferred consent [53]. The majority of
these participants would have consented to participate if
asked prior to enrolment (95.6 %, n = 204), reported a
positive experience with their method of enrolment,
were satisfied with who provided consent on their behalf
(92.7 %, n = 202), and were satisfied with the decision
taken on their behalf (93 %, n = 201).
Patients indicated varying degrees of acceptability to
enrolment using deferred consent for hypothetical stud-
ies. A greater proportion of patients preferred a deferred
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consent model (77 %, n = 240) to waived consent (23 %
of n = 240) in a hypothetical low-risk intervention study
when they were incapacitated (in a coma and on life
support) and a substitute decision maker was not
present [41]. When asked to rate the acceptability of this
consent model 48 % (n = 240) considered it highly ac-
ceptable and 37 % (n = 240) were neutral. However,
when a substitute decision maker was available, partici-
pants strongly preferred a third-party consent model
(76 % of n = 240). A second study evaluating the views
of patient–relative pairs following ICU admission sug-
gested acceptability of deferred consent in a non-
invasive study, even if patients were conscious (59 % to
86 %, n = 185 patients; 52 % to 68 %, n = 125 relatives),
with acceptability decreasing as study invasiveness in-
creased (50 % to 60 %, n = 185 patients; 46 % to 59 %
relatives) [33]. This last hypothetical scenario was of an
intervention study with a 5 % risk of serious complica-
tions and necessitated daily blood tests for 5 days. Sur-
veyed relatives of ICU patients also considered deferred
consent acceptable for drug trials (69 %, n = 42), but a
third of these respondents would not endorse this con-
sent model for a new drug (28 %, n = 29) [49].
Two studies considered the acceptability of deferred
consent in the design of trials in paediatric emergency
research. Results of a survey with families whose child
had experienced bacterial meningitis or meningococcal
septicaemia indicated that the majority (67 % of 68)
would be willing for their child to be enrolled under de-
ferred consent in a trial that evaluated the effectiveness
of two treatments already routinely in use for that condi-
tion (Gamble) [54]. In the event of their child’s death,
66 % of the bereaved respondents (n = 19) compared
with 37 % of non-bereaved respondents (n = 49)) would
have wanted to be told of their child’s enrolment at
some time. In a qualitative study examining parental
views on a proposed trial that aimed to evaluate an anti-
convulsant not yet in standard use for paediatric seizures,
participants considered deferred consent acceptable [55].
They recognised the need for this model for the feasible
conduct of research, saw value in research to inform treat-
ment for other children, and expressed trust in clinicians.
The acceptability of deferred consent was also dependent
on the perceived risk of the intervention. In both studies,
recommendations included the need for sensitivity around
timing of obtaining consent and, among bereaved parents,
of the individuality of the grief process [54, 55].
Research staff and regulators
Clinicians perceived deferred consent as one of a num-
ber of effective strategies to promote enrolment of critic-
ally ill children and adults into clinical studies [51, 56],
and the majority perceived the model as feasible and
ethical [51]. Clinicians who had experienced deferred
consent did not perceive an impact on their relationship
with parents/family of the child (59 %, n = 27) compared
with clinicians who had no experience of this model
(22 %, p = 0.01), suggesting that perceptions of the
model may shift with experience of using it [56]. Regula-
tors were, however, less comfortable approving deferred
consent for a hypothetical low-risk clinical trial than in
approving research conducted with third-party consent
and were more conservative in considering it acceptable
(8 %, n = 52 participants) compared with researchers
(43.3 %, n = 98 participants) [28].
Waived consent
Most of our included studies that addressed waived con-
sent (n = 29) were conducted in the USA (n = 25), in-
cluding four that addressed paediatric research under
waived consent [57–60]. These studies are governed by
the Federal and Drug Administrative legislation that re-
quires sufficient community consultation and public dis-
closure of this kind of research. Consequently, of the 22
studies that assessed research participant views for clin-
ical trials with adults [30, 41, 44, 61–75] and children
[57–60], more than half of these described public con-
sultations [44, 57–59, 64, 66, 67, 69, 76] or evaluations
of public disclosure [60, 72, 75]. This reflects the legisla-
tive context for this kind of research. In practice, con-
sent is usually sought later from the patient or a
surrogate decision maker, and this model may operate
much like the deferred consent model described earlier.
Potential research participants
The acceptability of waived consent research was
strongly influenced by participant beliefs and experi-
ences, for example, with involvement in research and/or
receiving medical care [70]. Several studies showed a
discrepancy between the concept of waived consent and
its application. For example, focus group participants
expressed strong ethical objections to research con-
ducted with waived consent, but these views shifted
when discussing their personal experiences [70]. Like-
wise, discrepancies existed between the proportion of re-
spondents who considered waived consent acceptable
and the proportion that would be willing to participate
[44, 61, 66, 67]. For example, of the attendees who took
part in a public consultation for a trial evaluating pre-
hospital interventions for seizures, 35.4 % of 1,901 gave
support for the concept of enrolment under waived con-
sent, whereas 51 % indicated willingness to take part
[44]. However, 82 % (n = 1901) of the respondents in this
study viewed it as beneficial. In a public survey for re-
suscitation research, 34 % (n = 530) of respondents en-
dorsed enrolment without prior consent, whereas 70 %
would be willing to participate [67]. This dropped to
49 % when the study involved a new treatment,
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suggesting that perceptions of risk may influence
decision-making. In contrast, a higher proportion of par-
ticipants in a public consultation for a trial evaluating
pre-hospital intervention for severe traumatic injury
were reported to ‘not object’ to the concept of enrol-
ment without prior consent (66 % of n = 150). Of these,
82 % (n = 150) were willing for the trial to continue;
however, < 67 % would want to be enrolled or be willing
to enrol their family member [66]. The authors noted
potential confusion, particularly among elderly attendees
about the concept of waived consent for research. Taken
together, these findings might suggest that while people
are more conservative in accepting the concept of
waived consent, possibly in a desire to protect the rights
of others, they are inherently altruistic in their desire to
contribute to research [44, 67].
Qualitative studies with patient populations most likely
to be affected by research conducted under waived con-
sent studies have suggested altruism and trust in the
medical community as key elements of patient’s
decision-making [62, 63, 65, 77]. In a small qualitative
study with stroke patients, interviewees were almost
unanimous (92 %, n = 11) in their endorsement of physi-
cians consenting to their participation if a surrogate de-
cision maker was not available [77]. Another qualitative
study with sudden cardiac death survivors found that pa-
tients were more concerned about risks and benefits of
study participation than with the method of consent or
aspects of study design such as randomisation [62].
Some interviewees in this study were also accepting of a
hypothetical study that involved some risk (1 in 10 000
risk of death) but little prospect of direct benefit. Results
from a focus group study with stroke or brain injury pa-
tients and their families, as well as those at risk of such
injury, suggest high levels of acceptability of research
conducted under waived consent [65]. This study also
highlighted confusion about key research concepts, such
as equipoise and randomisation, and identified the po-
tential for therapeutic misconception, where participants
perceive they will receive better treatment by their par-
ticipation in the trial. When interviewed, participants
and surrogate decision makers who had been involved in
a clinical trial comparing pre-hospital pharmacological
interventions for status epileptics, revealed similar mis-
understandings about the trial in which they had partici-
pated: 49 % of 59 respondents did not understand
randomisation, whereas 25 % of 61 respondents con-
fused research participation with long-term treatment
[63]. The majority of respondents, however, endorsed
their personal involvement (73 % of 61) and were
favourable toward research conducted under waived
consent in general (67 % of 61). Findings from these
studies reveal a more nuanced picture of participant ex-
perience and perception of waived consent research.
It is a legislative requirement to consult members of
the public about research conducted with waived con-
sent in the USA, and different methods have been used
to do this. Two-way communication processes, such as
public meetings. were more acceptable to members of
the public than one-way processes such as information
via the media or posters [64, 75]. Attendance at these
meeting is often low, however, and may not be represen-
tative of the community, calling into question the gener-
alisability of their findings [44, 61, 66, 75]. Additionally,
there is a need to define and target consultation efforts
at the community most likely to be affected by study en-
rolment [58, 72]. Two surveys conducted with a con-
venience sample of patients attending an emergency
department showed that public awareness of on-going
studies conducted under a consent waiver was generally
low (5 % of 530 and [67] 8 % of 497[72]). Just two of 61
participants and surrogate decision makers involved in a
clinical trial comparing pre-hospital pharmacological in-
terventions for status epileptics reported awareness of
the trial prior to enrolment [63].
We identified three studies concerned with paediatric
in-patient resuscitation research, all of which involved
parents reported from PICU, the community most likely
to be affected by this research [58–60]. Parents endorsed
the need for the research to be conducted without expli-
cit consent. They described high levels of distress and
feeling overwhelmed and fearful among the reasons for
not being able to take in information and provide pro-
spective consent [59]. However, they would want to be
made aware that the research was taking place and have
the option to opt out. A small group of parents who
would choose to opt out (15 % of 91) described the
stress related to that decision, the desire for the phys-
ician to choose their child’s treatment, and not wanting
to be a guinea pig as reasons for their choice [58]. A
range of methods for raising awareness of active studies
have been used including posters in the waiting room,
brochures, and verbal explanations of the study on ad-
mission. Following this approach, the majority of parents
surveyed in a PICU were aware of a paediatric resuscita-
tion study being conducted under waived consent (81 %
of 93) [60].
Research staff and regulators
In a European survey, waived consent was seen as ac-
ceptable for emergency traumatic brain injury research
by the majority of respondents (64 %, n = 79); however,
95 % indicated that proxy consent should also be sought
later [50]. Waived consent was considered effective and
feasible to increase enrolment of critically ill children
and adults into clinical studies; however, views on the
ethical acceptability of this approach varied among clini-
cians and researchers across Australia and New Zealand,
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(n = 276) [51]. In a hypothetical low-risk RCT, regulators
(4.1 %, n = 52) and researchers (22.4 % n = 98) were least
comfortable approving research conducted under waived
consent compared with other consent models.
In the United States, regulators experienced protocols
including waived consent as more complex and time
consuming to review [78, 79], with one study reporting a
mean time of 8.8 h, compared with 2.3 for studies not
conducted under EFIC [79]. A key challenge in applying
the law involved determining what constitutes adequate
community consultation and public notification [78].
Different methods, at times in combination with each
other, are used to achieve this goal [76, 79]. Regulators
perceived the US final rule regulation as ethically accept-
able in that it protected subjects (72 %, n = 46 [78, 79]
and correctly balanced this protection with the need to
conduct research (69 %, n = 45 [79]). We did not identify
any studies of regulator views of waived consent in
Europe.
Discussion
We reviewed publications on stakeholder acceptability of
consent models for emergency research participation
that might inform pandemic research preparedness. A
recognition exists across all stakeholder groups that
emergency research calls for a derivation of prospective
informed consent that is appropriate to this context.
Our findings suggest that alternative consent models are
broadly acceptable to potential research participants and
clinical or research staff. Less is known about regulator
views; however, one study suggests they may be more
conservative in approving third-party and deferred con-
sent [28]. Our findings also highlight issues and recom-
mendations that might enhance the acceptability of
these consent models and encourage recruitment in
emergency research that is likely to be applicable to fu-
ture epi/pandemic research.
Critically ill patients are a particularly vulnerable
population, and the ethical integrity of informed consent
processes is challenging even for those who have cap-
acity to provide consent prospectively [39]. However
many studies included in our review suggest that poten-
tial research participants do understand the difficulties
in conducting emergency research, support the need for
it, and accept the need for alternative consent models to
feasibly conduct it. Willingness to participate in research
and acceptance of alternative consent models was moti-
vated by perceived value in the importance of conduct-
ing research. Furthermore, participants appear motivated
by altruism, by trust in the medical community, and,
importantly, by perception of the risks and benefits to
taking part [62, 80]. In many included studies, the ac-
ceptability of consent models decreased in higher risk
scenarios. Issues of risk and trust are open to multiple
interpretations of meaning and several qualitative studies
revealed complex issues such as therapeutic misconcep-
tion, where patients tend to believe they will receive su-
perior treatment if they volunteer for a clinical trial. In a
pandemic, this might be particularly salient with overesti-
mations of the potential benefits of novel, but unproven
treatments, with patients viewing research participation as
a means to gain access to these treatments.
Direct experience also influenced the perception of ac-
ceptability to participants, researchers, or regulators. For
example, a higher proportion of participants enrolled in
a study using deferred consent found the model accept-
able [53] in comparison with other studies that evaluated
hypothetical scenarios [33, 41]. In addition, greater ac-
ceptability of deferred consent was observed among
those paediatric clinicians who had experience of the
model than those who did not [56]. Among research
regulators, acceptability of waived consent has developed
over time through experience of interpreting relevant le-
gislation [78, 79]. It is important, therefore, not only to
continue to evaluate the experience of these different
stakeholder groups but also to ensure representation of
such individuals in the development and regulatory
evaluation of study protocols. Additionally, on-going re-
search during inter-pandemic periods is needed to evalu-
ate the way in which these models were implemented
and the experience of all stakeholders in using them.
Application to a pandemic context
Most of the included studies were conducted in emer-
gency care but non-pandemic contexts, and the extent
to which we can generalise these findings to pandemic
emergency research requires investigation. Ethical ac-
ceptability is determined in part by the context in which
an action occurs, and different norms might be accept-
able for research conducted when a pandemic threat or
impact is low compared with when it is moderate or
high [19]. However, as others have argued, it is the cap-
acity of the patient rather than the urgency of a pan-
demic context that determines the acceptability of using
alternative consent models in research [16]. Not all
acutely ill patients presenting to emergency departments
will lack capacity, and findings from our review were
mixed about whether potential participants preferred to
consent themselves or for another to decide on their be-
half. Further, these consent models are not necessarily
applicable in other pandemic research contexts, such as
in non-emergency situations or in primary care, where
patients might be less unwell and more likely to have
capacity for providing prospective informed consent. Ra-
ther, the acceptability of the consent process in all set-
tings is judged proportionate to the likely outcome of
the illness and the likely burden associated with the
intervention under evaluation. For example, waived
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consent may be the preferred consent method for clin-
ical trials of routinely used treatments with an estab-
lished safety record, but unproven for the pandemic
pathogen [20]. Findings from our review were not ad-
equate to assess the acceptability of waived consent in
such a context. Moreover, pragmatic adaptations are
likely to be made. For example, in a pandemic influenza
outbreak, while third-party consent might be preferable,
this consent might be obtained through different com-
munication media such as verbally, by telephone or
through translators [4, 19]. Findings from our review
could not capture the utility or acceptability of these
pragmatic solutions.
Policy and legislative frameworks that guide the inclu-
sion of alternatives to prospective informed consent in
study protocols vary across countries and regions, im-
peding the ability to conduct harmonised multi-site tri-
als. This has been a particular concern in Europe with
regard to the legislative context guiding clinical trials in
European Union (EU) member states and its impact on
emergency research. The EU Clinical Trials Directive
2001/20/EC outlined the need for proxy consent before
enrolling participants who lack capacity, with no accom-
modation for studies in which treatment initiation
needed to occur within a narrow window of time [81].
The directive was not legally binding in all member
states. Consequently, about half of the EU member
states addressed this by permitting deferred consent in
their national law, whereas others made no provisions
for emergency research [82]. This lack of harmonization
presents a barrier to setting up and conducting multi-
site, clinical trials for pandemic research across Europe,
as researchers must navigate the different legal require-
ments for obtaining consent that are ratified in national
law. The European Parliament has now approved new
legislation in the form of a regulation (No. 536/2014),
which will be legally binding in all EU member states
and will allow deferred consent for emergency research
under certain circumstances [83]. This is an important
step for those wishing to set up pandemic research infra-
structures across Europe, where the need for a coordi-
nated approach is considered essential.
In addition to the need for scientific and ethical rigour,
pandemic research needs to be efficient in its design
feasibility and speed of set up [4, 84]. Clinical trials, for
example, need to be recruiting within weeks of pan-
demic onset to inform care decisions within that same
pandemic. The strain on hospital and ICU capacity to
respond to surge demands for clinical services will escal-
ate as the pandemic impact progresses [9, 10]. Ethically,
research processes should not rely unduly on clinician
time that would be best spent treating patients. Research
designs aligned with clinical practice, such as comparative
effectiveness research, [85] may allow efficient evaluation
of routinely used treatment procedures. Adaptive platform
trials, set up during inter-pandemic ‘peacetime’ might also
expedite inclusion and investigation of novel treatments
once an epidemic or pandemic is underway [86, 87]. A
platform trial is essentially a trial infrastructure in which
various interventions are evaluated within a master proto-
col. Interventions may be added or dropped once emer-
ging outcome data provides a pre-specified sufficiently
precise estimate of effectiveness or the lack thereof.
Response-adaptive trials alter the proportion of patients
randomised to various arms depending on emerging trial
data, with more participants randomised to the more suc-
cessful intervention. These innovative study designs have
raised unique ethical issues that have been debated
[88, 89], including questions about the validity of informed
consent procedures. Adaptive trials, for example, have
been described as more complex to explain to patients,
threatening patient’s ability to absorb and understand
what is being asked of them [88, 90]. However response-
adaptive designs may go some way to address therapeutic
misconceptions by narrowing the gap between what par-
ticipants believe (that trial participation will improve their
outcomes) and what they experience (that they will have a
greater chance of being allocated to a successful interven-
tion) [91]. Further investigation into the preferences, expe-
riences and acceptability of consent processes for novel
study designs is required.
While new study designs and alternative consent models
might hold the most promise for enabling pandemic re-
search to progress, they also attract more intensive regula-
tory review than more traditional designs [78, 92].
Findings from our review suggest that, while the experi-
ence of regulators has not been well evaluated, the regula-
tors appear to be more cautious in their judgments. This
is perhaps not unexpected: regulatory bodies are tasked
with protecting the rights, safety and dignity of research
participants, and their decisions impact public confidence
and trust in science. However the views of the public, par-
ticularly among research participants with direct experi-
ence of the use of these alternative consent models,
should inform regulatory decisions around acceptability.
Questions arise, however, about how best to engage with
members of the public so that they might contribute to
these decisions in a meaningful way.
While there is still much to learn in this complex
arena, it may be possible to suggest a few areas of good
practice informed by previous research in this area. Rec-
ommendations might include the following: prospective
informed consent in emergency research where patients
have capacity should respect patient preference for ver-
bal summary over written study information [29, 32]
and the opportunity to discuss the study prior to giving
consent [37]. When enrolling participants using third-
party consent, study information should be provided to
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participants or their legal guardians after the acute phase
of illness [48], decision concordance cannot be presumed
[31, 33, 93–95], and involving a second decision maker,
such as a treating clinician, might alleviate the burden [96]
for proxy decision makers [31, 33]. Sensitivity to timing
and the quality of the communication process, particularly
for bereaved relatives, is required when implementing de-
ferred consent [55]. Community consultation and engage-
ment should use multiple methods, the majority of which
should involve two-way communication [69, 75, 76]. Part-
nering with community members who represent target
populations might enhance a study’s exposure and accept-
ability [69]. Strategies for ensuring awareness for on-going
studies need to be developed [72] to better understand the
demographics and views of people who opt-out, thereby
allowing for targeted public awareness efforts [68].
Our review has also identified areas for future study.
Stakeholder perceptions related specifically to consent
models for pandemic-related research need evaluating.
Further research on regulator experience and views is
also required, particularly in the context of legislative
changes across Europe. Article 35 of Regulation No.
536/2014, effective from May 2016, makes provision for
obtaining informed consent in emergency situations that
will be legally binding across all member states [83].
Under this regulation, deferred consent will be legally
acceptable for emergency trials conducted in EU mem-
ber states; however, there is a lack of research with
adults who have experienced deferred consent. Further-
more, research on the unique set of challenges for
implementing alternative consent models in paediatric
emergency research, including the views of children or
young people, is also indicated.
Strengths and limitations
Other systematic reviews have been conducted in this area
that present a thorough and detailed examination of some
samples included in our review [80, 97, 98]. However, our
review set out to map the breadth and direction of evi-
dence on acceptability from multiple stakeholder perspec-
tives and to offer guidance for further research in some
key areas not identified in these other works. We devel-
oped a comprehensive search strategy that included grey
literature; however, this was not exhaustive. Decisions
taken to expedite our review may have introduced human
error, selection bias, and language of publication bias into
our sample. We were unable to assess the effect of publi-
cation bias. As appropriate to rapid review methodology,
we used narrative synthesis in our analysis [22], which
lacks the depth and detail of more formal methods such
as meta-analysis or meta-synthesis. The heterogeneity
across our sample, in context and in method, makes valid
comparisons across studies complex. While most of our
sample consisted of qualitative studies and surveys, there
is variability in terms of the way these studies were de-
signed, conducted, and reported [26]. For example, the
way in which survey questions were framed, the variability
in their aims (for example, assessing attitudes, opinions,
preferences, or behaviours), the use of hypothetical sce-
narios, and the different modes of survey administration
would all influence the results. While we assessed each
survey for quality to judge the validity of findings in their
own merit, we did not exclude any studies based on lower
quality assessments.
Conclusions
Alternative consent models will be needed to feasibly con-
duct some types of pandemic research, especially in relation
to emergency situations. Potential research participants,
their families, clinicians and research staff are broadly
accepting of these alternative methods of obtaining consent
for emergency research. The views of research regulators
are less clear, but it is important for regulators to consider
the views of various stakeholders in deciding on the direc-
tion of future regulation. Implementing these models re-
quires balancing ethical principles of individual autonomy
and social justice. In a pandemic, there may be a stronger
imperative to more easily facilitate research that might con-
fer significant benefit to society at large. These inherent
tensions will require further research and greater public in-
volvement in order to understand and document a full
range of key stakeholder experiences in implementing these
models, as well as to consider the acceptability to stake-
holders in a pandemic context and to inform regulatory
decision-making.
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